KDR and hepatocellular carcinoma: In addition, a phase I study (NCT 02942329, Table 2) to assess the efficacy and safety of combination of apatinib (a VEGFR-2 inhibitor) and SHR-1210 (an anti-PD-1 monoclonal antibody) in participants with advanced HCC showed encouraging clinical activity (PR rate 54.5%; ORR 50.0%; DCR 85.7%) (65).